55. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel-node
biopsy or nodal observation in melanoma. N Engl J Med
2006;355:1307–17.
56. Johnson TM, Sondak VK, Bichakjian CK, Sabel MS. The
role of sentinel lymph node biopsy for melanoma: evidence
assessment. J Am Acad Dermatol 2006;54:19–27.
57. Morton DL, Thompson JF, Cochran AJ, et al; MSLT Group.
Sentinel node biopsy for early-stage melanoma: accuracy
and morbidity in MSLT-I, an international multicenter trial.
Ann Surg 2005;242:302–11.
58. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel
and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival.
J Clin Oncol 2006;24:4464–71.
59. Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive
of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin
Oncol 2004;22:3677–84.
60. Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised
trial of interferon alpha-2a as adjuvant therapy in resected
primary melanoma thicker than 1. 5 mm without clinically
detectable node metastases. French Cooperative Group on
Melanoma. Lancet 1998;351:1905–10.
61. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative
Group. J Clin Oncol 1998;16:1425–9.
62. Eggermont AM, Suciu S, MacKie R, et al; EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate
doses of interferon alfa 2b versus observation in patients
with stage IIb/III melanoma (EORTC 18952): randomised
controlled trial. Lancet 2005;366:1189–96.
63. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United
Kingdom Coordinating Committee on Cancer Research
randomized study of adjuvant low-dose extended-duration
interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22:53–61.
64. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous
melanoma: the Eastern Cooperative Oncology Group Trial
EST 1684. J Clin Oncol 1996;14:7–17.
65. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol
2000;18:2444–58.
66. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose
interferon alfa-2b significantly prolongs relapse-free and
overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results
of intergroup trial E1694/S9512/C509801. J Clin Oncol
2001;19:2370–80.
67. Kirkwood JM, Manola J, Ibrahim J, et al; Eastern Cooperative
Oncology Group. A pooled analysis of eastern cooperative
oncology group and intergroup trials of adjuvant high-dose
interferon for melanoma. Clin Cancer Res 2004;10:1670– 7.
68. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with
interferon. N Engl J Med 2006;354:709–18.
69. Eggermont AM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of
adjuvant therapy with pegylated interferon alfa-2b versus
observation in resected stage III melanoma. J Clin Oncol
2012;30:3810–18.
70. Basseres N, Grob JJ, Richard MA, et al. Cost-effectiveness
of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology
department in France. Dermatology 1995;191:199–203.
71. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up
tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995;274:1703–5.
72. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the
American Joint Committee on Cancer staging system for
cutaneous melanoma. J Clin Oncol 2001;19:3635–48.
73. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year
experience overview. J Exp Clin Cancer Res 2000;19:21–34.
74. Middleton MR, Grob JJ, Aaronson N, et al. Randomized
phase III study of temozolomide versus dacarbazine in the
treatment of patients with advanced metastatic malignant
melanoma. J Clin Oncol 2000;18:158–66.
75. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus
dacarbazine in patients with metastatic melanoma. J Clin
Oncol 1999;17:2745–51.
76. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF
gene in human cancer. Nature 2002;417:949–54.
77. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated,
activated BRAF in metastatic melanoma. N Engl J Med
2010;363:809–19.
78. Chapman PB, Hauschild A, Robert C, et al; BRIM- 3 Study
Group. Improved survival with vemurafenib in melanoma
with BRAF V600E mutation. N Engl J Med 2011;364:
2507–16.
79. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF
V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707–14.
80. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous
squamous-cell carcinomas in patients treated with BRAF
inhibitors. N Engl J Med 2012;366:207–15.
81. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and
MEK inhibition in melanoma with BRAF V600 mutations. N
